ORIGINAL RESEARCH
Accepted on 28 May 2025
Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody
doi 10.3389/fphar.2025.1594213